Natalizumab (Tysabri) High Resolution MRI and Clinical Immunology-Correlative Observational Study in Multiple Sclerosis

Trial Profile

Natalizumab (Tysabri) High Resolution MRI and Clinical Immunology-Correlative Observational Study in Multiple Sclerosis

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms THRIFT-MS
  • Sponsors Biogen
  • Most Recent Events

    • 23 Dec 2014 Accrual to Date is 100 % according to the United Kingdom Clinical Research Network record.
    • 23 Dec 2014 Planned number of patients changed from 18 to 40 as reported by United Kingdom Clinical Research Network record.
    • 23 Dec 2014 Planned End Date changed from 31 Jan 2015 to 16 Oct 2014 as reported by United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top